PharmaCyte Biotech Inc [NASDAQ: PMCB] surged by $0.24 during the normal trading session on Tuesday and reaching a high of $1.2 during the day while it closed the day at $0.89.
PharmaCyte Biotech Inc stock has also gained 18.19% of its value over the past 7 days. However, PMCB stock has declined by -8.25% in the 3 months of the year. Over the past six months meanwhile, it has lost -16.82% and lost -49.14% year-on date.
The market cap for PMCB stock reached $6.05 million, with 6.80 million shares outstanding and 5.99 million shares in the current float. Compared to the average trading volume of 77.53K shares, PMCB reached a trading volume of 57580902 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about PharmaCyte Biotech Inc [PMCB]:
The Price to Book ratio for the last quarter was 0.14, with the Price to Cash per share for the same quarter was set at 1.98.
PMCB stock trade performance evaluation
PharmaCyte Biotech Inc [PMCB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.19. With this latest performance, PMCB shares dropped by -9.83% in over the last four-week period, additionally sinking by -16.82% over the last 6 months – not to mention a drop of -43.31% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PMCB stock in for the last two-week period is set at 55.21, with the RSI for the last a single of trading hit 0.1330, and the three-weeks RSI is set at 0.0984 for PharmaCyte Biotech Inc [PMCB]. The present Moving Average for the last 50 days of trading for this stock 0.9224, while it was recorded at 0.7068 for the last single week of trading, and 1.1247 for the last 200 days.
PharmaCyte Biotech Inc (PMCB) Capital Structure & Debt Analysis
According to recent financial data for PharmaCyte Biotech Inc. ( PMCB), the Return on Equity (ROE) stands at -2.33%, reflecting a slight decline for investors. The Return on Assets (ROA) is -1.95%, reflecting the company’s efficiency in generating profits from its assets. Additionally, PharmaCyte Biotech Inc’s Return on Invested Capital (ROIC) is -8.07%, showcasing its effectiveness in deploying capital for earnings.
PharmaCyte Biotech Inc (PMCB) Efficiency & Liquidity Metrics
Based on PharmaCyte Biotech Inc’s (PMCB) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
PharmaCyte Biotech Inc (PMCB) Efficiency & Liquidity Metrics
From an operational efficiency perspective, PharmaCyte Biotech Inc. (PMCB) effectively leverages its workforce, generating an average of -$1760000.0 per employee. The company’s liquidity position is robust, with a Current Ratio of 18.01% and a Quick Ratio of 18.01%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for PharmaCyte Biotech Inc [PMCB] stock
With the latest financial reports released by the company, PharmaCyte Biotech Inc posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.07/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PMCB.
PharmaCyte Biotech Inc [PMCB]: Institutional Ownership
There are presently around $6.38%, or 7.14%% of PMCB stock, in the hands of institutional investors. The top three institutional holders of PMCB stocks are: K2 PRINCIPAL FUND, L.P. with ownership of 0.33 million shares, which is approximately 3.8051%. VANGUARD GROUP INC, holding 0.19 million shares of the stock with an approximate value of $$0.38 million in PMCB stocks shares; and VANGUARD GROUP INC, currently with $$0.35 million in PMCB stock with ownership which is approximately 2.0519%.
